On June 26, China National Medical Products Administration Drug Evaluation Center website announced that novo-nordisk a/s's (NVO.US) Class 1 new drug amycretin tablet was approved for clinical use, intended to reduce weight in overweight or obese adult patients. Public information shows that this is a long-acting agonist of oral GLP-1 receptors and insulin receptors developed by novo-nordisk, a new generation of weight loss therapy.
According to the small phase 1 clinical study previously released by novo-nordisk, patients who received treatment with the product for 12 weeks experienced a weight loss of 13.1% (compared to 1.1% for the placebo group), demonstrating rapid weight loss effect and good clinical application potential.
According to information on the novo-nordisk website, amycretin is a long-acting synergistic agonist of GLP-1R and insulin receptors, currently being developed in two formulations: subcutaneous injection (once a week) and oral administration (once a day), and the current intended application is for obesity.
In March of this year, novo-nordisk released the latest clinical trial results for oral amycretin. This is a small phase 1 trial involving 16 patients. The weight loss after 12 weeks of treatment was 13.1%, compared to only 1.1% for the placebo group. In addition, amycretin exhibited good pharmacokinetic properties and similar good safety, tolerability, and adverse reactions as the GLP-1 class therapy it developed.